The FDA on February 22, 2017 approved REVLIMID® as maintenance therapy for patients with multiple myeloma following autologous stem cell transplant. In 2006, REVLIMID®, an orally administered thalidomide analogue, received FDA approval for use with dexamethasone in patients with multiple myeloma who received at least one prior therapy. In 2015, the indication was expanded for use in combination with dexamethasone for the treatment of patients with multiple myeloma, to include newly diagnosed multiple myeloma patients who are not eligible for autologous stem cell transplant. REVLIMID® is also approved in Myelodysplastic syndromes and Mantle Cell Lymphoma. REVLIMID® is a marketed by Celgene Corp.